Enfusion (NYSE:ENFN – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $54.39 million for the quarter.
Enfusion (NYSE:ENFN – Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The company had revenue of $52.94 million during the quarter, compared to analysts’ expectations of $53.98 million. On average, analysts expect Enfusion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Enfusion Price Performance
Shares of ENFN opened at $11.24 on Monday. Enfusion has a 1-year low of $7.83 and a 1-year high of $11.80. The stock has a market cap of $1.44 billion, a PE ratio of 280.95, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. The firm has a fifty day moving average price of $10.98 and a 200 day moving average price of $9.90.
Insider Buying and Selling at Enfusion
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on ENFN shares. Piper Sandler boosted their price target on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research report on Monday, December 23rd. William Blair restated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Stifel Nicolaus lifted their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $11.13.
Get Our Latest Stock Report on Enfusion
About Enfusion
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Further Reading
- Five stocks we like better than Enfusion
- The 3 Best Fintech Stocks to Buy Now
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- Are Penny Stocks a Good Fit for Your Portfolio?
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Basic Materials Stocks Investing
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.